DrugCite
Search

MIMPARA

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Mimpara Adverse Events Reported to the FDA Over Time

How are Mimpara adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Mimpara, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Mimpara is flagged as the suspect drug causing the adverse event.

Most Common Mimpara Adverse Events Reported to the FDA

What are the most common Mimpara adverse events reported to the FDA?

Vomiting
40 (2.22%)
Nausea
39 (2.17%)
Hypocalcaemia
29 (1.61%)
Drug Interaction
27 (1.5%)
Diarrhoea
25 (1.39%)
Hypotension
25 (1.39%)
Convulsion
23 (1.28%)
Abdominal Pain
21 (1.17%)
Blood Parathyroid Hormone Increased
21 (1.17%)
Calciphylaxis
21 (1.17%)
Cardiac Failure
19 (1.05%)
Show More Show More
Myalgia
18 (1%)
Hypertension
17 (.94%)
Paraesthesia
17 (.94%)
Depression
16 (.89%)
Hypercalcaemia
15 (.83%)
Abdominal Pain Upper
14 (.78%)
Transaminases Increased
14 (.78%)
Asthenia
13 (.72%)
Dizziness
13 (.72%)
Drug Ineffective
13 (.72%)
Myocardial Infarction
13 (.72%)
Blood Calcium Decreased
12 (.67%)
Pruritus
12 (.67%)
Fatigue
11 (.61%)
General Physical Health Deteriorati...
11 (.61%)
Intravascular Haemolysis
11 (.61%)
Muscular Weakness
11 (.61%)
Arthralgia
10 (.56%)
Blood Creatinine Increased
10 (.56%)
Cardiac Disorder
10 (.56%)
Dyspnoea
10 (.56%)
Renal Impairment
10 (.56%)
Sepsis
10 (.56%)
Weight Decreased
10 (.56%)
Death
9 (.5%)
Gastric Haemorrhage
9 (.5%)
Myocardial Ischaemia
9 (.5%)
Proteinuria
9 (.5%)
Renal Failure Acute
9 (.5%)
Tremor
9 (.5%)
Cerebral Haemorrhage
8 (.44%)
Grand Mal Convulsion
8 (.44%)
Hypersensitivity
8 (.44%)
Hypertensive Crisis
8 (.44%)
Loss Of Consciousness
8 (.44%)
Lung Disorder
8 (.44%)
Pneumonia
8 (.44%)
Shock
8 (.44%)
Vasculitis
8 (.44%)
Abdominal Discomfort
7 (.39%)
Confusional State
7 (.39%)
Decreased Appetite
7 (.39%)
Gait Disturbance
7 (.39%)
Gastrointestinal Disorder
7 (.39%)
High Turnover Osteopathy
7 (.39%)
Hypophosphataemia
7 (.39%)
Malaise
7 (.39%)
Melaena
7 (.39%)
Pancreatitis
7 (.39%)
Purpura
7 (.39%)
Somnolence
7 (.39%)
Status Epilepticus
7 (.39%)
Thrombocytopenia
7 (.39%)
Vertigo
7 (.39%)
Weight Increased
7 (.39%)
Abasia
6 (.33%)
Agitation
6 (.33%)
Alanine Aminotransferase Increased
6 (.33%)
Atrial Fibrillation
6 (.33%)
Blindness Unilateral
6 (.33%)
Blood Pressure Increased
6 (.33%)
Bronchitis
6 (.33%)
Cerebrovascular Accident
6 (.33%)
Gamma-glutamyltransferase Increased
6 (.33%)
Gastric Ulcer
6 (.33%)
Haemoglobin Decreased
6 (.33%)
Leukocytoclastic Vasculitis
6 (.33%)
Muscle Spasms
6 (.33%)
Parathyroid Tumour Benign
6 (.33%)
Parathyroidectomy
6 (.33%)
Pleural Effusion
6 (.33%)
Pulmonary Oedema
6 (.33%)
Skin Ulcer
6 (.33%)
Therapeutic Response Decreased
6 (.33%)
Arrhythmia
5 (.28%)
Aspartate Aminotransferase Increase...
5 (.28%)
Cardiac Arrest
5 (.28%)
Delirium
5 (.28%)
Depressed Level Of Consciousness
5 (.28%)
Diverticulum
5 (.28%)
Dyspepsia
5 (.28%)
Eosinophilia
5 (.28%)
Erectile Dysfunction
5 (.28%)
Haemorrhage Intracranial
5 (.28%)
Headache
5 (.28%)
Hypercalciuria
5 (.28%)
Leukopenia
5 (.28%)
Nephrolithiasis
5 (.28%)
Optic Ischaemic Neuropathy
5 (.28%)
Pain In Extremity
5 (.28%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Mimpara, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mimpara is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Mimpara

What are the most common Mimpara adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Mimpara, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mimpara is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Mimpara According to Those Reporting Adverse Events

Why are people taking Mimpara, according to those reporting adverse events to the FDA?

Hyperparathyroidism Secondary
370
Drug Use For Unknown Indication
157
Hyperparathyroidism Primary
32
Product Used For Unknown Indication
17
Pre-existing Disease
16
Hypercalcaemia
8
Show More Show More
Parathyroid Tumour Malignant
7
Hyperparathyroidism
5
Renal Failure Chronic
5
Renal Transplant
3
Renal Failure
3
Renal Impairment
2
Dialysis
2
Calciphylaxis
2
Hypoparathyroidism Secondary
1

Mimpara Case Reports

What Mimpara safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Mimpara. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Mimpara.